Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Key Terms

proteomics medical

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

single-molecule protein sequencing medical

Single-molecule protein sequencing is a laboratory method that reads the exact order of building blocks in a single protein molecule, similar to reading letters in a word rather than averaging many copies. For investors it matters because it promises far more sensitive and precise detection of disease markers, faster drug discovery and highly personalized diagnostics, which could create new markets or disrupt existing lab testing and therapeutics businesses.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, 151 West 42^nd Street, (4 Times Square), New York, NY 10036, on May 19, 2026.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, May 19, 2026, and Jeff Hawkins will participate in a fireside chat on the same day at 4:00 PM Eastern Time. A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to listen to the live webcast.

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428676337/en/

Investor and Media
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Source: Quantum-Si Incorporated